Neoadjuvant Niraparib Monotherapy for Newly Diagnosed Unresectable HRD-Positive High-Grade Serous Ovarian Cancer (NANT): A Multicenter, Prospective, Phase 2 Trial

SSRN Electronic Journal 2026 Preprint Open access

Read full text
Authors: Dan Liu, Zikun Peng, Wei Zhang, Cui Feng, Ping Wang, Jundong Li, Yuanjia Wen, Wanying Shan, Xia Yu, Guang‐Nian Zhao, Huayi Li, Jiahao Liu
+40 more Cheng Xu, Dongchen Zhou, Yu Xu, Fan Xiong, Bingquan Li, Ronghua Liu, Mingfu Wu, Zhen Li, Rong Liu, Gang Chen, Wen Pan, Qing Zhong, Ya Wang, Xiaofei Jiao, Xiao Li, Cheng Liu, Rutie Yin, Zhou Shengtao, Maomao Li, Kangjia Tao, Chujun Cai, Kairong Xiong, Wen Yang, Sisi Wu, Yikai Luo, Zhifeng Xia, Yu Dong, Zhi Wang, Jianhua Chi, Yaying Lin, Xingzhe Liu, Ning Jin, Yuxin Chen, Shanyang He, Yi Huang, Kun Song, Li Hong, Ding Ma, Yong Fang, Qinglei Gao
DOI: 10.2139/ssrn.6181452
Cited by: 0

Fields of Study & Subjects

PARP inhibition in cancer therapy Ovarian cancer diagnosis and treatment BRCA gene mutations in cancer

Publication details

Journal / source
SSRN Electronic Journal
Publication date
1 January 2026
Language
EN
Document type
Preprint